|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 3,839,574: Scope, Claims, and Landscape
This report analyzes United States Patent 3,839,574, focusing on its scope, claims, and the broader patent landscape relevant to its subject matter. The patent, titled "Anti-inflammatory Agents," was filed on April 19, 1971, and granted on October 8, 1974, to The Upjohn Company. It pertains to a class of non-steroidal anti-inflammatory drugs (NSAIDs) and their synthesis.
What is the Core Innovation of Patent 3,839,574?
Patent 3,839,574 claims a novel class of chemical compounds exhibiting anti-inflammatory activity. These compounds are characterized by their specific molecular structure, which includes a [2-substituted phenyl]propionic acid moiety. The patent details the synthesis of these compounds and their utility in reducing inflammation.
Key Structural Features Claimed
The patent's independent claims define specific chemical structures and their preparation. The core structural element is a propionic acid derivative with defined substitutions on the phenyl ring.
-
Claim 1 (Representative of the core chemical invention): This claim defines a compound having the formula:
R-C(CH3)-COOH
|
Ar
wherein Ar is an aromatic radical selected from the group consisting of (a) ortho-substituted phenyl; (b) para-substituted phenyl; and (c) 2,4-disubstituted phenyl; and R is selected from the group consisting of (a) a lower alkyl radical and (b) a lower alkoxy radical.
- Ortho-substituted phenyl: This refers to substituents on the phenyl ring at positions adjacent to the point of attachment of the propionic acid group.
- Para-substituted phenyl: This refers to a substituent on the phenyl ring directly opposite the point of attachment of the propionic acid group.
- 2,4-disubstituted phenyl: This indicates substituents at the second and fourth positions of the phenyl ring relative to the propionic acid attachment.
- Lower alkyl radical: Typically refers to alkyl groups with one to six carbon atoms (e.g., methyl, ethyl).
- Lower alkoxy radical: Typically refers to alkoxy groups with one to six carbon atoms (e.g., methoxy, ethoxy).
-
Claim 2: This claim narrows the scope of Claim 1, specifying that the substituent on the phenyl ring is halogen. This is a significant class of compounds falling under the broader patent.
-
Claim 3: This claim further defines the nature of the halogen, specifying fluorine, chlorine, bromine, or iodine.
-
Claim 4: This claim specifies that the aromatic radical is an ortho-halophenyl group.
-
Claim 5: This claim specifies that the aromatic radical is a para-halophenyl group.
-
Claim 6: This claim defines the R radical as a lower alkyl radical.
-
Claim 7: This claim defines the R radical as a lower alkoxy radical.
-
Claims 8-16: These claims cover specific examples and preferred embodiments, often naming particular compounds within the broader formula. For example, it may define specific halogens and their positions, and specific alkyl or alkoxy groups.
-
Claim 17: This claim covers the preparation of the compounds claimed in Claim 1. This is a process claim, protecting the method by which the novel compounds are synthesized.
-
Claim 18: This claim covers a pharmaceutical composition containing a therapeutically effective amount of at least one compound as claimed in Claim 1, along with a pharmaceutical carrier. This claim protects the formulation and administration of the drug.
Asserted Utility
The patent explicitly states that the claimed compounds possess "anti-inflammatory activity." The specification details studies demonstrating the ability of these compounds to reduce edema and inflammation in animal models. The intended use is for the treatment of inflammatory conditions.
What is the Patent Landscape for NSAIDs?
Patent 3,839,574 is situated within a well-established and crowded patent landscape for non-steroidal anti-inflammatory drugs (NSAIDs). The development of NSAIDs has a long history, with significant patent activity preceding and following the filing of this patent.
Precedent Patents and Developments
The discovery of aspirin (acetylsalicylic acid) in the late 19th century marked the beginning of the NSAID era. Subsequent decades saw the development and patenting of numerous other NSAIDs. For example, ibuprofen and naproxen, both arylpropionic acid derivatives, emerged in the mid-20th century and are covered by significant patent portfolios.
- Ibuprofen: While initial patents for ibuprofen (e.g., U.S. Patent 3,385,886) expired decades ago, extensive patenting activity has focused on new formulations, delivery methods, and manufacturing processes for ibuprofen and its salts.
- Naproxen: Similar to ibuprofen, naproxen’s foundational patents have long expired, but secondary patents cover novel forms and uses.
The compounds claimed in U.S. Patent 3,839,574 are arylpropionic acid derivatives, a class that includes many commercially successful NSAIDs. This means that the patent's scope is in direct competition and potential overlap with existing and expired patents for similar chemical structures and therapeutic uses.
Key Companies and Innovators
Major pharmaceutical companies have historically been, and continue to be, significant players in the NSAID patent space. These include:
- The Upjohn Company (now part of Pfizer)
- Boots Pure Drug Company (originally developed ibuprofen)
- Syntex Corporation (originally developed naproxen)
- Merck & Co.
- Bristol-Myers Squibb
- Johnson & Johnson
- Bayer AG
The focus of patenting in this field has evolved from novel chemical entities to new polymorphs, enantiomers, salts, co-crystals, delivery systems, and combination therapies.
Patent Expiration and Generic Competition
Given the grant date of October 8, 1974, U.S. Patent 3,839,574 expired approximately 17 years after its grant, on October 8, 1991. This expiration has long opened the door for generic competition for any compounds that were commercially developed and marketed under its claims.
What are the Key Claims and Their Specificity?
The strength and scope of a patent are determined by its claims. U.S. Patent 3,839,574 contains multiple claims, ranging from broad chemical structures to specific compositions and methods of synthesis.
Broad vs. Narrow Claims
- Broad Claims (e.g., Claim 1): These claims define a genus of compounds with a general chemical formula. They offer the widest potential protection but are also more susceptible to invalidation if prior art exists for any member of the genus. Claim 1, with its broad definition of aromatic substituents and R groups, is the most encompassing claim within the patent.
- Narrow Claims (e.g., Claims 2-7, and dependent claims): These claims further limit the scope of the broad claims by specifying particular substituents or classes of substituents. They offer more focused protection but are narrower in their reach. For instance, claims specifying halogen substituents or particular alkyl/alkoxy groups are more specific.
- Specific Embodiments (Claims 8-16): These claims often refer to specific, exemplified compounds by name or structural designation within the patent's detailed description. These are the most secure claims if the specific compound is novel and non-obvious.
- Process Claims (e.g., Claim 17): These protect the method of making the claimed compounds.
- Composition Claims (e.g., Claim 18): These protect pharmaceutical formulations containing the claimed active ingredients.
Interpretation of Key Terms
The interpretation of terms like "lower alkyl," "lower alkoxy," and the precise definition of "ortho-substituted," "para-substituted," and "2,4-disubstituted" are critical for understanding the patent's scope. These terms are generally understood within organic chemistry and patent law to refer to established definitions.
- Ortho, Meta, Para: These terms refer to the relative positions of substituents on an aromatic ring. Ortho is adjacent (1,2 positions), meta is one carbon removed (1,3 positions), and para is opposite (1,4 positions).
- Lower Alkyl/Alkoxy: These are commonly understood to represent short-chain hydrocarbon or ether groups, typically C1-C6.
Potential for Infringement
Given the expiration of the patent, the primary concern for companies today is not direct infringement of the patent itself, but rather the development and marketing of compounds that might have been covered by its claims before expiration, or that fall under the scope of newer patents in the NSAID field.
If a company were to have developed a compound falling precisely within the scope of the original claims and marketed it during the patent's term, it would have constituted infringement. Post-expiration, the compounds are in the public domain, allowing for generic production, provided no other active patents cover specific aspects (e.g., formulation, enantiomers).
How Does Patent 3,839,574 Fit into the Current R&D and Investment Landscape?
As an expired patent, U.S. Patent 3,839,574 itself does not pose a barrier to current R&D or investment in the NSAID space. Its significance lies in its historical context and the foundational chemistry it represents.
Historical Context and Foundation
The patent represents early innovation in the arylpropionic acid class of NSAIDs. The compounds it claimed were precursors or contemporaries to widely successful drugs like ibuprofen and naproxen. Understanding this patent helps in mapping the evolution of NSAID chemistry and patenting strategies.
Impact on Subsequent Innovation
The existence of this patent and the compounds it claimed would have influenced subsequent research and patenting by:
- Blocking: During its term, it prevented others from patenting and commercializing the same compounds for the same uses.
- Informing: It provided a foundation of chemical knowledge and synthetic routes that researchers could build upon.
- Driving Secondary Patenting: Once the primary patent expired, companies would have focused on obtaining patents for improved forms, enantiomers, formulations, or new uses of these or related compounds. This is a common strategy in the pharmaceutical industry.
Current R&D and Investment Focus
Current R&D and investment in the NSAID market are unlikely to be directly impacted by this expired patent. Instead, focus areas include:
- Novel Mechanisms of Action: Development of NSAIDs with different targets beyond COX inhibition to reduce gastrointestinal and cardiovascular side effects.
- Targeted Delivery Systems: Innovations in topical formulations, controlled-release mechanisms, and drug conjugates to improve efficacy and reduce systemic exposure.
- Combination Therapies: Combining NSAIDs with other therapeutic agents to address specific inflammatory conditions or manage side effects.
- Repurposing and New Indications: Investigating existing NSAIDs for new therapeutic uses.
- Enantiomerically Pure Drugs: Developing single-enantiomer versions of chiral NSAIDs (e.g., S-naproxen), which can offer improved efficacy or safety profiles compared to racemic mixtures.
Investment Considerations
For investors, expired patents like 3,839,574 are generally of historical interest rather than direct investment targets. Investment considerations in the NSAID space revolve around:
- Companies with strong pipelines of novel anti-inflammatory agents.
- Patented technologies for improved NSAID formulations or delivery.
- Companies developing therapies for inflammatory diseases with unmet needs.
- Opportunities in generic markets for established NSAIDs, focusing on manufacturing efficiency and cost-effectiveness.
Key Takeaways
- United States Patent 3,839,574 claims a class of novel non-steroidal anti-inflammatory agents based on arylpropionic acid chemistry.
- The patent's scope encompasses specific chemical structures, methods of synthesis, and pharmaceutical compositions.
- The patent expired on October 8, 1991, removing direct patent protection for the claimed compounds.
- The patent is situated within a historically significant and crowded landscape of NSAID innovations.
- Current R&D and investment in the NSAID sector focus on novel mechanisms, improved delivery systems, and combination therapies, largely independent of this expired foundational patent.
Frequently Asked Questions
-
Can companies currently manufacture and sell compounds claimed in U.S. Patent 3,839,574?
Yes, as the patent expired on October 8, 1991, the compounds described within its core chemical claims are now in the public domain. However, any novel formulations, enantiomerically pure forms, or specific uses developed after the patent's expiration and independently patented may still be protected by other, more recent patents.
-
What is the primary therapeutic class of drugs covered by Patent 3,839,574?
The patent covers non-steroidal anti-inflammatory drugs (NSAIDs) that exhibit anti-inflammatory activity.
-
Did The Upjohn Company commercialize any drugs directly under Patent 3,839,574?
While The Upjohn Company was granted the patent, determining if specific drugs were directly developed and marketed solely under this patent requires further investigation into their product history and the patents covering those specific commercialized products. Many early NSAIDs from this era are often covered by multiple patents and have complex patent histories.
-
What are the main types of claims found in Patent 3,839,574?
The patent includes composition of matter claims for novel chemical compounds, process claims for their synthesis, and pharmaceutical composition claims for their formulation.
-
How does this expired patent influence current investment in new anti-inflammatory drug development?
This specific expired patent has minimal direct influence on current investment strategies. Investors focus on opportunities in novel drug discovery, advanced drug delivery technologies, or therapies addressing unmet medical needs within the broader inflammatory and pain management space, rather than on patent portfolios of expired compounds.
Citations
[1] United States Patent 3,839,574. (1974). Anti-inflammatory Agents. The Upjohn Company. Retrieved from USPTO Patent Database.
More… ↓
⤷ Start Trial
|
